focus -WSS

focus

author：hotspot 2025-10-01 02:16:02 - browse：98568

Humana sign -- health business coverage from STAT — Humana’s Medicare Advantage business is faring even worse than the company let on last week. Ed Reinke/AP

Humana’s Medicare Advantage business is faring even worse than the company let on last week, with “unprecedented” numbers of older adults getting medical care and busting through its tactics for holding up payment.

The country’s second largest private Medicare insurer disclosed Thursday it’s projecting roughly half the profit in 2024 that investors had expected. The news comes a week after Humana already lowered its projected 2023 profit, which still came in at north of $3 billion before taxes.

The stock market’s punishment was swift and decisive, sinking Humana’s share price by roughly 12% at midday. Outgoing CEO Bruce Broussard worked to calm nerves on the company’s investor call, reiterating his confidence in MA. Humana went all-in on the program when it announced last year it would wind down its employer business, but that comes as regulators are beefing up scrutiny of MA plans.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Indian pharmaceutical industry in denial over drug

WSS

Gene therapy for Afghan refugees’ infant will be fully covered

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Top private equity targets in 2023: cardiology, clinical trials, lasers

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Devoted Health’s losses in Medicare Advantage persist

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

focus

focus

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD: Venture capital, Gilead, and more M&A

Trump demands the U.S. pay no more for drugs than other countries … again

What’s missing from the debate over nursing home staff minimums

What does generative AI mean for health care? We asked experts

Bernie brings in new pharma CEOs to talk drug prices

New air purifier tech could be key to improving indoor air quality

Hospitals struggle to profit from CAR

23andMe had bad news about my health. I wish a person had delivered it

Problems with a popular proposal to regulate AI in health care

focus

Study identifies new proteins linked to dementia risk 25 years later

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Why Novartis is going to walk from its acquisition of MorphoSys

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

knowledge

hotspot

entertainment

focus